Nek­tar up­dates PhIb atopic der­mati­tis da­ta amid Lil­ly suit; Cure, Frac­etat join forces on AAV plat­form

Nek­tar Ther­a­peu­tics has un­veiled up­dat­ed re­sults from a Phase Ib tri­al of its atopic der­mati­tis (AD) can­di­date, rezpe­galdesleukin, in the midst of a case against ex-part­ner Eli Lil­ly.

High-dose rezpe­galdesleukin pro­duced a mean 72% im­prove­ment in af­fect­ed body sur­face area at 12 weeks ver­sus place­bo’s 36% (p=0.00158). The drug al­so saw a mean 78% im­prove­ment in the der­ma­tol­ogy life qual­i­ty in­dex and a 58% im­prove­ment in the pa­tient-ori­ent­ed eczema mea­sure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER